title: 68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs.
abstract: Abundant expression of somatostatin receptors (SSTR) is frequently identified in differentiated neuroendocrine tumors and may serve as potential target for diagnostic imaging and treatment. This article discusses the "theranostic approach" of SSTR-targeting compounds including an overview of its role for diagnosis, staging and restaging, discussing its way to being established in clinical routine, and giving an outlook about further potentially relevant developments.
authors.affiliation: Department of Nuclear Medicine, Universitätsklinikum Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Germany.
authors.forename: Rudolf A
authors.initials: RA
authors.lastname: Werner
authors.forename: Christina
authors.initials: C
authors.lastname: Bluemel
authors.forename: Martin S
authors.initials: MS
authors.lastname: Allen-Auerbach
authors.forename: Takahiro
authors.initials: T
authors.lastname: Higuchi
authors.forename: Ken
authors.initials: K
authors.lastname: Herrmann
mesh_terms: D005710:Gallium Radioisotopes / Q000627:therapeutic use; D006801:Humans; D008187:Lutetium / Q000627:therapeutic use; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000532:radiotherapy*; D011868:Radioisotopes / Q000627:therapeutic use; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D017481:Receptors, Somatostatin / Q000378:metabolism; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
chemical_list: D005710:Gallium Radioisotopes; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; D015021:Yttrium Radioisotopes; D008187:Lutetium